"I am honored to join C-Path and to lead the CPAD Consortium in its mission to drive therapeutic innovation for Alzheimer's disease," said Dr. Tatton. "There is so much momentum in AD research today, ...

In healthy brains, immune cells called microglia patrol for damage, clearing away debris and harmful proteins. But in the presence of the APOE4 protein-;the most important genetic risk factor for ...

The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. That’s why scientists search for therapies ...

Studies have not found evidence that aluminum contributes to Alzheimer’s disease development. But research is ongoing, and you could be a part of it. Alzheimer’s is a progressive disease that ...

Critical Path Institute today announced key leadership appointments: Diane Stephenson, Ph.D., has been promoted to Vice President of Neurology, and Nadine Tatton, Ph.D., has been welcomed as the new ...

It is thought that people with Alzheimer's disease are more susceptible to infections than healthy people of the same age. As the diseases that cause dementia are very complex, it is unlikely that ...

This view of Alzheimer's as a circuit disorder that ultimately disrupts cognition is speculative, Lein stressed. But the new study's cellular mapping supports reframing Alzheimer's beyond just a ...

For the first time, new drugs have been approved in the UK that can slow down memory and thinking decline in early Alzheimer’s disease. But research never stops! Here we explore three promising new ...

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...

Maher, Pamela 2023. Ferroptosis in Health and Disease. p. 461. Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ...

Beta-amyloid plaques are protein clumps that form in the brain and block the neural paths that send signals throughout the ...

Roche may seek an accelerated U.S. approval of its experimental Alzheimer’s disease drug trontinemab ... precedent to seek an abbreviated approval path, as the company plans to look for an ...